Abstracts

Citation

D Bhattacharya, A Gupta, C Tierney, S Huang, M Peters, T Chipato, F Martinson, D Dula, K George, N Chakhtoura, KL Klingman, D Gnanashanmugam, J Currier, MG Fowler. Hepatotoxicity in HIV+ Postpartum Women Initiating Efavirenz-Containing Regimens. Presented at: IAS 2017.

Citation

K Patel, J Lindsey, M Hernan, K Angelidou, G Aldrovandi, P Palumbo for the IMPAACT P1060 Study Team. Long-term metabolic implications of initiating lopinavir/ritonavir-based regimens for infants and children: a follow-up study of IMPAACT P1060. Presented at: IAS 2017.

Citation

M Van Schalkwyk, A Bekker, E Decloedt, GB Theron, MF Cotton, B Best, E Capparelli, A Stek, J Wang, M Mirochnick on behalf of the IMPAACT P1026s Protocol team. Pharmacokinetics of Rifampin and Isoniazid during Pregnancy and Postpartum in South African Women. Presented at: IAS 2017.

Citation

K Patel, B Simth, IJ Collins, R BGoodall, E Abrams, A Sohn, T Mohamed, R Van Dyke, P Rojo, K Wools-Kaloustian, J Pinto, A Edmonds, I Marete, M Paul, H Nuwaqaba-Biribonwoha, V Leroy, M-A Davies, R Vreeman, CIPHER Cohort Collaboration Duration of Second-line Proi. Outcomes of second-line antiretroviral therapy (ART) in HIV-infected children: a CIPHER cohort collaboration global analysis. Presented at: IAS 2018; 2018 Jul 25.

Citation

J Aizire, KM Brooks, M Mirochnick, P Flynn, M Cababasay, JJ Kiser, G Siberry, T Fenton, K Butler, MG Fowler, PROMISE study team. Intracellular concentrations of tenofovir diphosphate (TFV-DP) during pregnancy in the PROMISE study: Description and relationship with adverse pregnancy outcomes. Presented at: IAS 2018.

Citation

D Clarke, E Acosta, A Chain, M Cababasay, J Wang, H Teppler, E Smith, R Hazra, S Popson, B Graham, K Calabrese, Y Bryson , S Spector, M Mirochnick. IMPAACT P1110: Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: Dose-finding study in infants born to mothers receiving raltegravir-containing ART. Presented at: IAS 2018.

Citation

T Ruel, E Acosta, R Singh, C Alvero, T Fenton, K George, S Popson, E Townley, R Hazra, C Brothers, C Vavro, A Buchanan, A Wiznia, IMPAACT P1093 team. Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to 6 years: Results from IMPAACT P1093. Presented at: IAS 2018.

Citation

J Momper, B Best, J Wang, A Stek, DE Shapiro, K George, E Barr, K Rungruengthanakit, E Smith, N Chakhtoura, EV Capparelli, M Mirochnick. Pharmacokinetics of darunavir boosted with cobicistat during pregnancy and postpartum. Presented at: IAS 2018.

Citation

JD Momper, B Best, J Wang, A Stek, TR Cressey, S Burchett, R Kreitchmann, DE Shapiro, E Smith, N Chakhtoura, EV Capparelli, M Mirochnick, IMPAACT P1026s Protocol team. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. Presented at: CROI 2018.

Citation

M Owor, C Tierney, L Ziemba, R Browning, J Moye, B Graham, C Reding, D Costello, J Norman, L Wiesner, E Hughes, M Whalen, L Purdue, BT Mmbaga, P Kamthunzi, R Kawalazira, K Nathoo, S Bradford, A Coletti, R Aweeka, P Musoke. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. Presented at: IAS 2019.